Navigation Links
Premier Research Group plc and Octagon Research Solutions, Inc. Announce Strategic Partnership
Date:4/29/2008

PHILADELPHIA, April 29 /PRNewswire/ -- Premier Research Group plc (AIM: PRG), the international pharmaceutical services group, and Octagon Research Solutions, Inc., a leader in the electronic transformation of clinical R&D in the life sciences industry, today announce the formalization of a partnership agreement to provide a broader solution set.

This new partnership combines Octagon's expertise in electronic submissions with Premier Research's extensive clinical expertise across a wide array of therapeutic areas. The partnership enables Premier Research to offer Octagon's electronic submission capabilities as part of its Regulatory Affairs services and for Octagon to offer Premier's Regulatory development and scientific strategy.

James Ottinger, vice president of Global Consulting and Compliance for Premier Research noted, "Our partnership with Octagon broadens our services by offering Octagon's proven expertise in the technical aspects of electronic submissions while we continue to focus on our core strengths of regulatory strategy and consulting. We are pleased to be working with an organization that also values our deep commitment to being a 'solution provider' for our clients."

"Premier Research has a solid history of consistent, quality delivery that aligns with our own high standard of operation. We believe that the collaboration will ultimately provide a strong product for our valued customers," commented Jim Walker, chairman and CEO, Octagon Research Solutions, Inc.

About Premier Research

Premier Research is a leading solutions-driven CRO leveraging their commitment to therapeutic focus and scientific expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. They are leaders in clinical research for Analgesia, CNS, Infectious Disease, and Oncology and have a wealth of experience in medical device and pediatric research. Premier Research has 29 offices and
'/>"/>

SOURCE Premier Research Group plc
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2

Related biology technology :

1. ARUP Laboratories and Premier Extend Contract for Reference Laboratory Testing Services
2. Premier Research Appoints Melissa Jones as Vice President, International Business Development
3. Premier Research Appoints Global Head of Human Resources
4. Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research
5. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
6. Five Medical Technology Companies Host Premier Event for Cardiothoracic Surgeons
7. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Dendreon Appoints Hans Bishop as Chief Operating Officer 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3
Breaking Biology News(10 mins):Abundance of a look-alike species clouds population status of a million dollar fish 2Abundance of a look-alike species clouds population status of a million dollar fish 3Old hay and Alpine ibex horns reveal how grasslands respond to climate change 2Old hay and Alpine ibex horns reveal how grasslands respond to climate change 3UT Southwestern receives $700,000 from HHMI to promote medical education of Ph.D. students 2Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China 5562 1Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China 5562 2Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China 5562 3ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity 5559 1ECRI Institute Sees Upward Trend in Hospital Medical Technology Evaluation Activity 5559 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 1Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 3Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 4Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5556 5